$COGT

After Microsoft’s results, investors focused on AI monetization. Amazon shares jumped 15.3% post-close as AWS revenue rose 37% YoY, fastest in 18 quarters, and AI and chips run rates topped $25B. Apple fell 7.4% on outlook concerns. Treasuries rose to 4.71% and Brent to $87.93. The piece also lists options trades including LWLG and SITE.

Cogent Biosciences (NASDAQ:COGT) said it filed a New Drug Application with the U.S. FDA for bezuclastinib to treat advanced systemic mastocytosis, citing encouraging results from its APEX key trial. CEO Andrew Robbins said the company is working with the FDA on three submissions and expects initial approvals by end-2026.

The article cites BioPharma Dive and PitchBook data showing autoimmune and cancer drug developers received over 40% of venture financing rounds in the first half of 2026, with about $9B invested total and $3.9B in cancer and immune therapies. It then lists 10 U.S.-listed biotech stocks screened for market cap over $2B and forward P/E under 10, including Cogent Biosciences (COGT), which filed an FDA NDA for bezuclastinib and targets initial approvals by end-2026.

Cogent Biosciences (NASDAQ:COGT) presented early preclinical data for its experimental mutant-selective JAK2 inhibitor CGT1145 at the European Hematology Association Congress in Stockholm. The company said CGT1145 showed over 100-fold selectivity for JAK2 V617F versus wild-type JAK2 and JAK1/3, with strong oral bioavailability. CEO Andrew Robbins said Cogent plans to file an FDA Investigational New Drug application later this year.

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001622229 0001622229 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2

Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.

Cogent Biosciences' (COGT) shares are under scrutiny after new SUMMIT trial data for bezuclastinib in NonAdvanced Systemic Mastocytosis. Despite significant past returns, current trading at a 10.9x Price-to-Book ratio, much higher than the biotech industry average of 2.7x, suggests investors are placing high value on its pipeline. The company is unprofitable with growing losses, indicating that the market anticipates future success from its drug programs like bezuclastinib, but also highlighting risks of clinical setbacks and shareholder dilution.

Cogent Biosciences announced positive 48-week data from its SUMMIT trial for bezuclastinib in NonAdvanced systemic mastocytosis (NonAdvSM), showing a 56% improvement in Total Symptom Score and high rates of serum tryptase reduction and normalization. The results also indicated clinically meaningful improvements in bone mineral density, supporting bezuclastinib's potential as a disease-modifying agent. The company also reported inducement equity grants for new employees.

Cogent Biosciences has announced its anticipated commercial and clinical milestones for 2026, focusing on bezuclastinib and its precision therapies portfolio. Key plans include submitting New Drug Applications (NDAs) for bezuclastinib in multiple indications like NonAdvSM, AdvSM, and GIST, with potential commercial launch in the second half of 2026. The company also expects to submit Investigational New Drug (IND) applications for novel pan-KRAS(ON) and JAK2 V617F inhibitors, supported by a strong financial position of approximately $900 million.

Cogent Biosciences (COGT) stock surged by 7.14% following positive pivotal trial results for its drug bezuclastinib in treating systemic mastocytosis. Despite facing significant financial challenges like negative profitability and declining revenue, the successful clinical outcomes and subsequent analyst upgrades have positioned the stock for potential growth. The company plans to submit a new drug application for bezuclastinib to the FDA by the first half of 2026.